» Articles » PMID: 16959611

Gain of Function of Mutant P53: the Mutant P53/NF-Y Protein Complex Reveals an Aberrant Transcriptional Mechanism of Cell Cycle Regulation

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2006 Sep 9
PMID 16959611
Citations 237
Authors
Affiliations
Soon will be listed here.
Abstract

This article investigates the mechanistic aspects of mutant p53 "gain of function" in response to DNA damage. We show that mutant forms of p53 protein interact with NF-Y. The expression of cyclin A, cyclin B1, cdk1, and cdc25C, as well as the cdk1-associated kinase activities, is upregulated after DNA damage, provoking a mutant p53/NF-Y-dependent increase in DNA synthesis. Mutant p53 binds NF-Y target promoters and, upon DNA damage, recruits p300, leading to histone acetylation. The recruitment of mutant p53 to the CCAAT sites is severely impaired upon abrogation of NF-YA expression. Endogenous NF-Y, mutant p53, and p300 proteins form a triple complex upon DNA damage. We demonstrate that aberrant transcriptional regulation underlies the ability of mutant p53 proteins to act as oncogenic factors.

Citing Articles

Decoding the functional impact of the cancer genome through protein-protein interactions.

Fu H, Mo X, Ivanov A Nat Rev Cancer. 2025; 25(3):189-208.

PMID: 39810024 DOI: 10.1038/s41568-024-00784-6.


Role of artificial intelligence in cancer detection using protein p53: A Review.

Patil M, Bihari A Mol Biol Rep. 2024; 52(1):46.

PMID: 39658610 DOI: 10.1007/s11033-024-10051-4.


From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.

Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M Biomark Res. 2024; 12(1):137.

PMID: 39538363 PMC: 11565275. DOI: 10.1186/s40364-024-00676-9.


Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.

Valenti F, Ganci F, Sacconi A, Lo Sardo F, DAndrea M, Sanguineti G J Mol Med (Berl). 2024; 102(12):1485-1501.

PMID: 39480521 DOI: 10.1007/s00109-024-02499-5.


TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).

Tornesello M Int J Mol Med. 2024; 55(1).

PMID: 39450536 PMC: 11554381. DOI: 10.3892/ijmm.2024.5448.